<!doctype html> <html> <head><style>
             table { border-collapse: collapse; }
             th, td {
               word-wrap: break-word;
               max-width: 100%;
               font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
               border-bottom: 1px solid #ddd;
               padding: 5px;
               text-align: left;
             }
            tr:hover {background: #f4f4f4;}
            tr:hover .highlighted {background: repeating-linear-gradient(
                    45deg,
                    #ffff99,
                    #ffff99 10px,
                    #f4f4f4 10px,
                    #f4f4f4 20px
                  );}
           .highlighted { background-color: #ffff99; }
          </style></head><body><h2>Cancer immunotherapy</h2><br> <b>Section Title</b>: FDA-approved antibodies <br><b>Table Section Text</b>: <i> None </i> <br> <table>
<tr> <th colspan=1 rowspan=1 > Antibody </th><th colspan=1 rowspan=1 > Brand name </th><th colspan=1 rowspan=1 > Type </th><th colspan=1 rowspan=1 > Target </th><th colspan=1 rowspan=1 > Approval date </th><th colspan=1 rowspan=1 > Approved treatment(s) </th></tr>
<tr> <td colspan=1 rowspan=1 > Alemtuzumab </td><td colspan=1 rowspan=1 > Campath </td><td colspan=1 rowspan=1 > humanized </td><td colspan=1 rowspan=1 > CD52 </td><td colspan=1 rowspan=1 > 2001 </td><td colspan=1 rowspan=1 > B-cell chronic lymphocytic leukemia (CLL) </td></tr>
<tr> <td colspan=1 rowspan=1 > Atezolizumab </td><td colspan=1 rowspan=1 > Tecentriq </td><td colspan=1 rowspan=1 > humanized </td><td colspan=1 rowspan=1 > PD-L1 </td><td colspan=1 rowspan=1 > 2016 </td><td colspan=1 rowspan=1 > bladder cancer </td></tr>
<tr> <td colspan=1 rowspan=1 > Avelumab </td><td colspan=1 rowspan=1 > Bavencio </td><td colspan=1 rowspan=1 > human </td><td colspan=1 rowspan=1 > PD-L1 </td><td colspan=1 rowspan=1 > 2017 </td><td colspan=1 rowspan=1 > metastatic Merkel cell carcinoma </td></tr>
<tr> <td colspan=1 rowspan=1 > Ipilimumab </td><td colspan=1 rowspan=1 > Yervoy </td><td colspan=1 rowspan=1 > human </td><td colspan=1 rowspan=1 > CTLA4 </td><td colspan=1 rowspan=1 > 2011 </td><td colspan=1 rowspan=1 > metastatic melanoma </td></tr>
<tr> <td class="highlighted"  colspan=1 rowspan=1 > Ofatumumab </td><td colspan=1 rowspan=1 > Arzerra </td><td class="highlighted"  colspan=1 rowspan=1 > human </td><td class="highlighted"  colspan=1 rowspan=1 > CD20 </td><td colspan=1 rowspan=1 > 2009 </td><td colspan=1 rowspan=1 > refractory CLL </td></tr>
<tr> <td colspan=1 rowspan=1 > Nivolumab </td><td colspan=1 rowspan=1 > Opdivo </td><td colspan=1 rowspan=1 > human </td><td colspan=1 rowspan=1 > PD-1 </td><td colspan=1 rowspan=1 > 2014 </td><td colspan=1 rowspan=1 > unresectable or metastatic melanoma, squamous non-small cell lung cancer, Renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, classical hodgkin lymphoma </td></tr>
<tr> <td colspan=1 rowspan=1 > Pembrolizumab </td><td colspan=1 rowspan=1 > Keytruda </td><td colspan=1 rowspan=1 > humanized </td><td colspan=1 rowspan=1 > PD-1 </td><td colspan=1 rowspan=1 > 2014 </td><td colspan=1 rowspan=1 > unresectable or metastatic melanoma, squamous non-small cell lung cancer (NSCLC), Hodgkin's lymphoma, Merkel-cell carcinoma (MCC), primary mediastinal B-cell lymphoma (PMBCL), stomach cancer, cervical cancer </td></tr>
<tr> <td colspan=1 rowspan=1 > Rituximab </td><td colspan=1 rowspan=1 > Rituxan, Mabthera </td><td colspan=1 rowspan=1 > chimeric </td><td colspan=1 rowspan=1 > CD20 </td><td colspan=1 rowspan=1 > 1997 </td><td colspan=1 rowspan=1 > non-Hodgkin lymphoma </td></tr>
<tr> <td colspan=1 rowspan=1 > Durvalumab </td><td colspan=1 rowspan=1 > Imfinzi </td><td colspan=1 rowspan=1 > human </td><td colspan=1 rowspan=1 > PD-L1 </td><td colspan=1 rowspan=1 > 2017 </td><td colspan=1 rowspan=1 > bladder cancer non-small cell lung cancer </td></tr>
</table> <br> <h3>Sentence(s)</h3>1. Ofatumumab is a human antibody to CD20.<br> 2. Ofatumumab is a human antibody that binds to CD20.<br> 3. The Ofatumumab is a human antibody that binds to CD20. <br> <br><br><b>Categories:</b><br><b>Numerical:</b> Uses math skills for writing the sentence. Uses math operations (addition, subtraction, average, etc.), counting numbers, frequency of items, etc.<br> <b>Commonsense:</b> Uses commonsene knowledge about situations humans encounter in everyday life â€“ physical objects, word meanings, social or physical domains, peoples' intentions, etc.<br> <b>Temporal:</b> When concepts related to time and temporal aspects are required for writing the sentence. Duration, ordering, typical time of events, time differences between events.<br> <b>Table:</b> Writing the sentence requires knowledge from the table except: the highlighted cells, row and column headers, table titles, section titles, section texts.<br> <b>Out of Table:</b> Writing the sentence requires external knowledge that is not present in the table nor common sense. Knowledge about some specific domain comes under this category. </body></html>
